Cresco Labs (CRLBF) EBITDA Margin (2020 - 2026)
Cresco Labs' (CRLBF) quarterly EBITDA Margin came in at 7.38% in Q1 2026, down 81.0% YoY from 38.86% in Q1 2025, and up 115.79% on a QoQ basis from 46.76% in Q4 2025.
Cresco Labs (CRLBF) EBITDA Margin (2020 - 2026) Analysis & Trends
Cresco Labs (CRLBF) has 7 years of EBITDA Margin data on file, last reported at 7.38% in Q1 2026.
- Quarterly EBITDA Margin fell 81.0% year-over-year to 7.38% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 4.74% (down 2440.0% YoY) and the FY2025 annual result came in at 4.27%, down 3186.0% from the prior year.
- EBITDA Margin grew to 7.38% in Q1 2026, from 46.76% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 29.13% in Q4 2023 to a low of 46.76% in Q4 2025.
- A 5-year average of 11.47% and a median of 14.84% in 2022 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin soared 2300 bps — and 2025, when it tumbled 7036 bps.
- Tracing CRLBF's EBITDA Margin over 5 years: stood at 14.84% in 2022, then jumped by 96 bps to 29.13% in 2023, then slipped by 19 bps to 23.6% in 2024, then plunged by 298 bps to 46.76% in 2025, then jumped by 116 bps to 7.38% in 2026.
- The last three EBITDA Margin figures came in at 7.38% (Q1 2026), 46.76% (Q4 2025), and 10.81% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Cresco Labs | 292.94 Mn | 228.83 Mn | 86.95 Mn | 7.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.38% |
| Dec 31, 2025 | -46.76% |
| Sep 30, 2025 | 10.81% |
| Jun 30, 2025 | 9.86% |
| Mar 31, 2025 | 8.20% |
| Dec 31, 2024 | 23.60% |
| Sep 30, 2024 | 28.52% |
| Jun 30, 2024 | 17.56% |
| Mar 31, 2024 | 15.82% |
| Dec 31, 2023 | 29.13% |
| Sep 30, 2023 | 25.74% |
| Jun 30, 2023 | -5.43% |
| Mar 31, 2023 | 1.85% |
| Dec 31, 2022 | 14.84% |
| Sep 30, 2022 | 19.83% |
| Jun 30, 2022 | 10.39% |
| Mar 31, 2022 | 23.67% |
| Dec 31, 2021 | 26.17% |
| Sep 30, 2021 | 32.98% |
| Jun 30, 2021 | 21.68% |